nach oben

Current Obstetrics and Gynecology Reports

Erschienen in:

06.04.2020 | Family Planning (A Burke, Section Editor)

Recent Advances in the Medical Management of Early Pregnancy Loss

verfasst von: Jade M. Shorter, Courtney A. Schreiber, Sarita Sonalkar

Erschienen in: Current Obstetrics and Gynecology Reports | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To provide an update on advances in medical management of early pregnancy loss, including the addition of mifepristone pretreatment to existing regimens.

Recent Findings

The utilization of misoprostol for medical management of early pregnancy loss has been studied extensively and is established as a safe and effective treatment. Two recent randomized controlled trials have demonstrated that the addition of mifepristone pretreatment significantly increases the effectiveness of misoprostol and a large body of data demonstrate the excellent safety profile of mifepristone. However, the Food and Drug Administration Risk Evaluation and Mitigation Strategy restrictions impose a major barrier to mifepristone use.

Summary

The addition of mifepristone to existing misoprostol regimens has significantly improved the effectiveness and patient-centered benefits of medical management of early pregnancy loss. Mifepristone restrictions need to be removed in order to decrease the barriers to women obtaining evidence-based care.

ACOG Practice Bulletin No. 200. Summary: early pregnancy loss. Obstet Gynecol. 2018;132(5):1311–3.CrossRef

Hemminki E. Treatment of miscarriage: current practice and rationale. Obstet Gynecol. 1998;91(2):247–53.PubMedCrossRef

Wang X, Chen C, Wang L, Chen D, Guang W, French J. Conception, early pregnancy loss, and time to clinical pregnancy: a population-based prospective study. Fertil Steril. 2003;79(3):577–84.PubMedCrossRef

Warburton D, Fraser FC. Spontaneous abortion risks in man: data from reproductive histories collected in a medical genetics unit. Am J Hum Genet. 1964;16:1–25.PubMedPubMedCentral

Ventura SJ, Curtin SC, Abma JC, Henshaw SK. Estimated pregnancy rates and rates of pregnancy outcomes for the United States, 1990-2008. Natl Vital Stat Rep. 2012;60(7):1–21.PubMed

Trinder J, Brocklehurst P, Porter R, Read M, Vyas S, Smith L. Management of miscarriage: expectant, medical, or surgical? Results of randomised controlled trial (miscarriage treatment (MIST) trial). BMJ. 2006;332(7552):1235–40.PubMedPubMedCentralCrossRef

Henshaw RC, Cooper K, el-Refaey H, Smith NC, Templeton AA. Medical management of miscarriage: non-surgical uterine evacuation of incomplete and inevitable spontaneous abortion. BMJ. 1993;306(6882):894–5.PubMedPubMedCentralCrossRef

Chung TK, Cheung LP, Leung TY, Haines CJ, Chang AM. Misoprostol in the management of spontaneous abortion. Br J Obstet Gynaecol. 1995;102(10):832–5.PubMedCrossRef

Committee on Practice B-G. The American College of Obstetricians and Gynecologists Practice Bulletin no. 150. Early pregnancy loss. Obstet Gynecol. 2015;125(5):1258–67.CrossRef

10.

Chen BA, Creinin MD. Contemporary management of early pregnancy failure. Clin Obstet Gynecol. 2007;50(1):67–88.PubMedCrossRef

11.

Zhang J, Gilles JM, Barnhart K, Creinin MD, Westhoff C, Frederick MM, et al. A comparison of medical management with misoprostol and surgical management for early pregnancy failure. N Engl J Med. 2005;353(8):761–9.PubMedCrossRef

12.

Robledo C, Zhang J, Troendle J, Barnhart K, Creinin MD, Westhoff C, et al. Clinical indicators for success of misoprostol treatment after early pregnancy failure. Int J Gynaecol Obstet. 2007;99(1):46–51.PubMedPubMedCentralCrossRef

13.

Schreiber CA, Creinin MD, Reeves MF, Harwood BJ. Mifepristone and misoprostol for the treatment of early pregnancy failure: a pilot clinical trial. Contraception. 2006;74(6):458–62.PubMedCrossRef

14.

Kollitz KM, Meyn LA, Lohr PA, Creinin MD. Mifepristone and misoprostol for early pregnancy failure: a cohort analysis. Am J Obstet Gynecol. 2011;204(5):386 e1–6.CrossRef

15.

Neilson JP, Hickey M, Vazquez J. Medical treatment for early fetal death (less than 24 weeks). Cochrane Database Syst Rev. 2006;3:CD002253.

16.

Neilson JP, Gyte GM, Hickey M, Vazquez JC, Dou L. Medical treatments for incomplete miscarriage. Cochrane Database Syst Rev. 2013;3:CD007223.

17.

• Lemmers M, Verschoor MA, Kim BV, Hickey M, Vazquez JC, Mol BWJ, et al. Medical treatment for early fetal death (less than 24 weeks). Cochrane Database Syst Rev. 2019;6:CD002253 This systematic review reported similar effectiveness for various routes of misoprostol administration.PubMed

18.

Petrou S, McIntosh E. Women's preferences for attributes of first-trimester miscarriage management: a stated preference discrete-choice experiment. Value Health. 2009;12(4):551–9.PubMedCrossRef

19.

Creinin MD, Schwartz JL, Guido RS, Pymar HC. Early pregnancy failure--current management concepts. Obstet Gynecol Surv. 2001;56(2):105–13.PubMedCrossRef

20.

• Al Wattar BH, Murugesu N, Tobias A, Zamora J, Khan KS. Management of first-trimester miscarriage: a systematic review and network meta-analysis. Hum Reprod Update. 2019;25(3):362–74 This systematic review and meta-analysis concludes that mifepristone may improve the efffectiveness of existing misoprostol regimens. They call for further researh to help improve inconsistencies between current studies.CrossRef

21.

Gemzell-Danielsson K, Bygdeman M, Aronsson A. Studies on uterine contractility following mifepristone and various routes of misoprostol. Contraception. 2006;74(1):31–5.PubMedCrossRef

22.

Fiala C, Gemzel-Danielsson K. Review of medical abortion using mifepristone in combination with a prostaglandin analogue. Contraception. 2006;74(1):66–86.PubMedCrossRef

23.

Baulieu EE. The steroid hormone antagonist RU486. Mechanism at the cellular level and clinical applications. Endocrinol Metab Clin N Am. 1991;20(4):873–91.CrossRef

24.

Baulieu EE. On the mechanism of action of RU486. Ann N Y Acad Sci. 1991;626:545–60.PubMedCrossRef

25.

Schreiber CA, Creinin MD, Harwood B, Murthy AS. A pilot study of mifepristone and misoprostol administered at the same time for abortion in women with gestation from 50 to 63 days. Contraception. 2005;71(6):447–50.PubMedCrossRef

26.

Duan H, Wang NG. Effects of tyrosine alone and tyrosine in combination with RU486 on early pregnancy in mice and the mechanism of action. Yao Xue Xue Bao. 1997;32(8):583–5.PubMed

27.

Cheng L, Kelly RW, Thong KJ, Hume R, Baird DT. The effect of mifepristone (RU486) on the immunohistochemical distribution of prostaglandin E and its metabolite in decidual and chorionic tissue in early pregnancy. J Clin Endocrinol Metab. 1993;77(3):873–7.PubMed

28.

Creinin MD, Fox MC, Teal S, Chen A, Schaff EA, Meyn LA, et al. A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. Obstet Gynecol. 2004;103(5 Pt 1):851–9.PubMedCrossRef

29.

Creinin MD, Schreiber CA, Bednarek P, Lintu H, Wagner MS, Meyn LA, et al. Mifepristone and misoprostol administered simultaneously versus 24 hours apart for abortion: a randomized controlled trial. Obstet Gynecol. 2007;109(4):885–94.PubMedCrossRef

30.

Schreiber C, Creinin M. Mifepristone in abortion care. Semin Reprod Med. 2005;23(1):82–91.PubMedCrossRef

31.

Schaff EA, Fielding SL, Westhoff C, Ellertson C, Eisinger SH, Stadalius LS, et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial. JAMA. 2000;284(15):1948–53.PubMedCrossRef

32.

van den Berg J, Gordon BB, Snijders MP, Vandenbussche FP, Coppus SF. The added value of mifepristone to non-surgical treatment regimens for uterine evacuation in case of early pregnancy failure: a systematic review of the literature. Eur J Obstet Gynecol Reprod Biol. 2015;195:18–26.PubMedCrossRef

33.

•• Schreiber CA, Creinin MD, Atrio J, Sonalkar S, Ratcliffe SJ, Barnhart KT. Mifepristone pretreatment for the medical management of early pregnancy loss. N Engl J Med. 2018;378(23):2161–70 This randomized controlled trial demonstrated signifcantly increased rates of complete uterine evacuation and decreased rates of uterine aspiration for the addition of mifepristone to misoprostol.PubMedPubMedCentralCrossRef

34.

•• Sinha P, Suneja A, Guleria K, Aggarwal R, Vaid NB. Comparison of mifepristone followed by misoprostol with misoprostol alone for treatment of early pregnancy failure: a randomized double-blind placebo-controlled trial. J Obstet Gynaecol India. 2018;68(1):39–44 This randomized controlled trial showed that mifepristone pretreatment to misoprostol significantly improves the efficay of misoprostol alone.PubMedCrossRef

35.

Rausch M, Lorch S, Chung K, Frederick M, Zhang J, Barnhart K. A cost-effectiveness analysis of surgical versus medical management of early pregnancy loss. Fertil Steril. 2012;97(2):355–60.PubMedCrossRef

36.

Dalton VK, Liang A, Hutton DW, Zochowski MK, Fendrick AM. Beyond usual care: the economic consequences of expanding treatment options in early pregnancy loss. Am J Obstet Gynecol. 2015;212(2):177 e1–6.CrossRef

37.

Nagendra D, Schreiber CA, Koelper N, Sonalkar S, Loza-Avalos S, Harvie H. Cost effectiveness of mifepristone pretreatment for the medical management of nonviable early pregnancy [09OP]. Obstet Gynecol. 2019;133:6.CrossRef

38.

Westhoff CL. A better medical regimen for the management of miscarriage. N Engl J Med. 2018;378(23):2232–3.PubMedCrossRef

39.

Kulier R, Kapp N, Gulmezoglu AM, Hofmeyr GJ, Cheng L, Campana A. Medical methods for first trimester abortion. Cochrane Database Syst Rev. 2011;11:CD002855.

40.

American College of O, Gynecologists. Practice bulletin no. 143: medical management of first-trimester abortion. Obstet Gynecol. 2014;123(3):676–92.CrossRef

41.

Henney JE, Gayle HD. Time to reevaluate U.S. mifepristone restrictions. N Engl J Med. 2019;381(7):597–8.PubMedCrossRef

42.

Mifeprex RSG, Raymond EG, Blanchard K, Blumenthal PD, Cleland K, Foster AM, et al. Sixteen years of overregulation: time to unburden Mifeprex. N Engl J Med. 2017;376(8):790–4.CrossRef

43.

Cleland K, Smith N. Aligning mifepristone regulation with evidence: driving policy change using 15 years of excellent safety data. Contraception. 2015;92(3):179–81.PubMedCrossRef

44.

Pymar HC, Creinin MD, Schwartz JL. Mifepristone followed on the same day by vaginal misoprostol for early abortion. Contraception. 2001;64(2):87–92.PubMedCrossRef

45.

Rossi B, Creinin MD, Meyn LA. Ability of the clinician and patient to predict the outcome of mifepristone and misoprostol medical abortion. Contraception. 2004;70(4):313–7.PubMedCrossRef

Titel: Recent Advances in the Medical Management of Early Pregnancy Loss
verfasst von: Jade M. Shorter
Courtney A. Schreiber
Sarita Sonalkar
Publikationsdatum: 06.04.2020
Verlag: Springer US
Erschienen in: Current Obstetrics and Gynecology Reports / Ausgabe 2/2020
Elektronische ISSN: 2161-3303
DOI: https://doi.org/10.1007/s13669-020-00282-0

Neu im Fachgebiet Gynäkologie und Geburtshilfe

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Recent Advances in the Medical Management of Early Pregnancy Loss

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Single-Port Laparoscopic Surgery for Endometrial Cancer: a Systematic Review

Treatment of Midlife Women with Chronic Low Back Pain—Opioids Are a Last-Resort Option

Telemedicine for Medication Abortion: The Time Is Now

Pharmacokinetics of Hormonal Contraception in Individuals with Obesity: a Review

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie